source
- J&J’s Erleada reduces metastasis or death risk by 20% in early‑stage prostate cancer studyJohnson & Johnson presented data on its hormone therapy drug Erleada at the ASCO 2026 meeting. The study focused on men with early‑stage prostate cancer who received the drug around the time of sur…
- Orphan drug sales projected to exceed 21% of prescription market by 2032, driven by strong pipeline and policy supportOrphan drug developers continue to see robust sales growth even as the broader pharmaceutical industry faces pricing and policy turbulence. The latest Evaluate Orphan Drugs Report highlights that s…